Literature DB >> 22959355

Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis.

Ji Young Hong1, Gyeong Seo Jung, Hyunjung Kim, Young Mi Kim, Hye Jon Lee, Sang-Nae Cho, Se Kyu Kim, Joon Chang, Young Ae Kang.   

Abstract

OBJECTIVE: This study evaluated inducible protein 10 (IP-10) as a diagnostic biomarker for specific tuberculosis (TB) infection and evaluated the ability of IP-10 to distinguish between active TB and latent TB infection (LTBI).
METHODS: Forty-six patients with active pulmonary TB, 22 participants with LTBI, and 32 non-TB controls were enrolled separately. We measured IP-10 in serum and in supernatants from whole blood stimulated with TB-specific antigens.
RESULTS: TB antigen-dependent IP-10 secretion was significantly increased in the active TB patients and LTBI subjects compared with controls, but did not differ significantly between the active TB patients and LTBI subjects. Serum IP-10 levels were higher in active TB than in LTBI (174.9 vs. 102.7pg/ml, p=0.002). The respective rates of positive responders of TB antigen-dependent IP-10 were 97.8%, 90.9%, and 12.5% in active TB, LTBI, and non-TB controls, respectively. For serum IP-10, 87.5%, 45.5%, and 9.5% of responders were positive in the respective groups.
CONCLUSIONS: The IP-10 response to TB antigen may constitute a specific biomarker for TB infection, but does not by itself distinguish between active TB and LTBI. Serum IP-10 may enhance the diagnostic performance when used in combination with another marker.
Copyright © 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959355     DOI: 10.1016/j.ijid.2012.07.013

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  11 in total

1.  Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production.

Authors:  Yun Hee Jeong; Yun-Gyoung Hur; Hyejon Lee; Sunghyun Kim; Jang-Eun Cho; Jun Chang; Sung Jae Shin; Hyeyoung Lee; Young Ae Kang; Sang-Nae Cho; Sang-Jun Ha
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

2.  C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings.

Authors:  Mark W Tenforde; Nikhil Gupte; David W Dowdy; David M Asmuth; Ashwin Balagopal; Richard B Pollard; Patcharaphan Sugandhavesa; Javier R Lama; Sandy Pillay; Sandra W Cardoso; Jyoti Pawar; Breno Santos; Cynthia Riviere; Noluthando Mwelase; Cecilia Kanyama; Johnstone Kumwenda; James G Hakim; Nagalingeswaran Kumarasamy; Robert Bollinger; Richard D Semba; Thomas B Campbell; Amita Gupta
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

3.  Cytokine Kinetics in the First Week of Tuberculosis Therapy as a Tool to Confirm a Clinical Diagnosis and Guide Therapy.

Authors:  Alice L den Hertog; María Montero-Martín; Rachel L Saunders; Matthew Blakiston; Sandra Menting; Jeevan B Sherchand; Lovett Lawson; Olanrewaju Oladimeji; Saddiq T Abdurrahman; Luis E Cuevas; Richard M Anthony
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

4.  Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response.

Authors:  Ruschca Jacobs; Stephanus Malherbe; Andre G Loxton; Kim Stanley; Gian van der Spuy; Gerhard Walzl; Novel N Chegou
Journal:  Oncotarget       Date:  2016-09-06

5.  Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated Adults.

Authors:  Piotr Szpakowski; Franck Biet; Camille Locht; Małgorzata Paszkiewicz; Wiesława Rudnicka; Magdalena Druszczyńska; Fabrice Allain; Marek Fol; Joël Pestel; Magdalena Kowalewicz-Kulbat
Journal:  J Immunol Res       Date:  2015-08-03       Impact factor: 4.818

6.  Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls.

Authors:  Ida Wergeland; Jörg Assmus; Anne Ma Dyrhol-Riise
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

7.  Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV.

Authors:  Katherine Farr; Resmi Ravindran; Luke Strnad; Emily Chang; Lelia H Chaisson; Christina Yoon; William Worodria; Alfred Andama; Irene Ayakaka; Priscilla Bbosa Nalwanga; Patrick Byanyima; Nelson Kalema; Sylvia Kaswabuli; Winceslaus Katagira; Kyomugisha Denise Aman; Emmanuel Musisi; Nuwagaba Wallen Tumwine; Ingvar Sanyu; Robert Ssebunya; J Lucian Davis; Laurence Huang; Imran H Khan; Adithya Cattamanchi
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

8.  Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis.

Authors:  Xia Qiu; Tao Xiong; Xiaojuan Su; Yi Qu; Long Ge; Yan Yue; Yan Zeng; Wenxing Li; Peng Hu; Dezhi Mu
Journal:  BMC Infect Dis       Date:  2019-10-30       Impact factor: 3.090

9.  Gaps in Study Design for Immune Parameter Research for Latent Tuberculosis Infection: A Systematic Review.

Authors:  Mariana Herrera; Cristian Vera; Yoav Keynan; Zulma Vanessa Rueda
Journal:  J Immunol Res       Date:  2020-04-21       Impact factor: 4.818

10.  High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis.

Authors:  Jessica L Pedersen; Simone E Barry; Nilesh J Bokil; Magda Ellis; YuRong Yang; Guangyu Guan; Xiaolin Wang; Alen Faiz; Warwick J Britton; Bernadette M Saunders
Journal:  Clin Transl Immunology       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.